ViMRT
}  
 
Home   
< Docs   

 HBV mutation literature information.


  Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development.
 PMID: 21831732       2011       Digestive and liver disease
Abstract: An exception is rtM204I, which can derive from a transition or a transversion.


  The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
 PMID: 21860069       2011       Antiviral chemistry & chemotherapy
Abstract: rtA194T reduced replication by <40%, whereas rtL180M+rtM204V, Abstract: METHODS: A plasmid containing a wild-type 1.3 genome length genotype D HBV laboratory strain was used as a parent for PC, BCP, rtA194T+-rtL180M+rtM204V, rtL180M+rtM204V and rtM204I mutants.


  The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.
 PMID: 21871497       2011       Antiviral research
Abstract: HepG2 stable cell lines permanently expressing wild type (WT) HBV or the main HBV mutants resistant to lamivudine and/or adefovir (rtL180M+rtM204V, rtV173L+rtL180M+rtM204V, rtM204I, rtL180M+rtM204I, rtN236T, rtA181V, rtA181V


  Four-year follow-up of two chronic hepatitis B recipients of hepatitis B surface antigen-positive cadaveric liver grafts from asymptomatic carriers.
 PMID: 21883736       2011       Hepatology research
Abstract: HBV breakthrough occurred in one recipient at the month 12 post-OLT, with detectable serum HBV-DNA (740 copies/mL) and tyrosine-methionine-aspartate-aspartate motif mutation (rtM204I and rtM204V).


  Evolution of hepatitis B virus during long-term therapy in patients with chronic hepatitis B.
 PMID: 21911882       2011       Annals of hepatology
Abstract: During ADV and LAM treatment, one patient developed ADV plus LAM resistance mutations (rtI163V+rtL180M+rtA181V+rtN236T), in this case, HBV strains harbouring polymerase mutations did not develop LAM associated rtM204V/I primary mutation.
Abstract: RESULTS: Three patients developed LAM resistance mutations (2 presented rtM204I and one rtL180M+rtM204V/I) and one patient showed


  Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B.
 PMID: 21915864       2011       Journal of medical virology
Abstract: LAM substitution mutations L180M + M204V/I were found in six out of seven cases, with an accompanying V173L mutation in three cases.


  Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naive to antiviral drugs.
 PMID: 21920388       2011       Antiviral research
Abstract: HBV reverse-transcriptase (RT) region was sequenced and analyzed for 20 mutations, confirmed by in vitro studies as associated with resistance to nucleos(t)ide HBV-RT inhibitors (rtL80I/V-rtI169T-rtV173L-rtL180M-rtA181T/V/S-rtT184A/S/G/C-rtA194T-rtS202C/G/I-


  Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B.
 PMID: 21933446       2011       BMC cancer
Abstract: Virological factors including HBV-DNA level, genotype, precore G1896A, BCP A1762T/G1764A, rtM204I/V, rtA181T and pre-S internal deletion mutations as well as clinical variables including subsequent use of rescue drugs were submitted for outcome analysis.
Method: The methods to detect HBV basal core promoter (BCP) A1762T/G1764A mutations, precore stop codon
Table: M204I


  Molecular epidemical characteristics of Lamivudine resistance mutations of HBV in southern China.
 PMID: 21959623       2011       Medical science monitor
Discussion: Other mutations and mixed combinations were also observed (rtM204I+rtV207M/L, rtM204I+rtV173L, rtM204I+rtS213T, rtM204V+rtL180M+rtV173L/M, rtM204V+rtL180M+rt PMID: 22007495       2011       Sichuan da xue xue bao. Yi xue ban
Abstract: The type of genotype mutation were all rtM204I.



Browser Board

 Co-occurred Entities




   Filtrator